Cumberland Pharmaceuticals (NASDAQ:CPIX) Releases Earnings Results

Cumberland Pharmaceuticals (NASDAQ:CPIX) posted its quarterly earnings data on Tuesday. The specialty pharmaceutical company reported ($0.06) EPS for the quarter, Zacks reports. Cumberland Pharmaceuticals had a positive return on equity of 7.48% and a negative net margin of 6.97%.

Cumberland Pharmaceuticals Stock Down 3.6%

Shares of CPIX stock traded down $0.10 on Tuesday, reaching $2.66. 43,826 shares of the company’s stock traded hands, compared to its average volume of 507,983. Cumberland Pharmaceuticals has a 12-month low of $1.04 and a 12-month high of $7.25. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.17 and a current ratio of 1.30. The company has a market capitalization of $39.79 million, a P/E ratio of -12.09 and a beta of -0.41. The business’s 50 day moving average price is $3.34 and its two-hundred day moving average price is $3.90.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cumberland Pharmaceuticals stock. XTX Topco Ltd bought a new stake in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 10,280 shares of the specialty pharmaceutical company’s stock, valued at approximately $34,000. XTX Topco Ltd owned approximately 0.07% of Cumberland Pharmaceuticals at the end of the most recent reporting period. 15.51% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on CPIX. Wall Street Zen lowered Cumberland Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, August 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.